questionId
int64 337
65.5k
| question
stringlengths 11
209
| doc_id
stringlengths 8
8
| page_ids
stringlengths 15
680
| answers
stringlengths 5
436
| answer_page_idx
int64 0
20
| data_split
stringclasses 1
value |
|---|---|---|---|---|---|---|
1,180 | when was this last updated ? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['august 1, 2002', 'August 1, 2002'] | 0 | train |
1,181 | Who is the lead responsible person for draft justification for actos 508? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['Amy Hagaman/Alfonso Perez'] | 0 | train |
1,195 | Which is the core organization of Takeda pharmaceutical Company? | lmjf0226 | ['lmjf0226_p0', 'lmjf0226_p1', 'lmjf0226_p2', 'lmjf0226_p3', 'lmjf0226_p4', 'lmjf0226_p5', 'lmjf0226_p6', 'lmjf0226_p7', 'lmjf0226_p8', 'lmjf0226_p9', 'lmjf0226_p10', 'lmjf0226_p11', 'lmjf0226_p12', 'lmjf0226_p13', 'lmjf0226_p14', 'lmjf0226_p15', 'lmjf0226_p16'] | ['Pharmaceutical development Division', 'Pharmaceutical Development Division'] | 1 | train |
1,196 | Who made the opening remarks ? | lmjf0226 | ['lmjf0226_p0', 'lmjf0226_p1', 'lmjf0226_p2', 'lmjf0226_p3', 'lmjf0226_p4', 'lmjf0226_p5', 'lmjf0226_p6', 'lmjf0226_p7', 'lmjf0226_p8', 'lmjf0226_p9', 'lmjf0226_p10', 'lmjf0226_p11', 'lmjf0226_p12', 'lmjf0226_p13', 'lmjf0226_p14', 'lmjf0226_p15', 'lmjf0226_p16'] | ['Dr. Kitazawa'] | 1 | train |
1,197 | When is the clinical expert meeting scheduled? | lmjf0226 | ['lmjf0226_p0', 'lmjf0226_p1', 'lmjf0226_p2', 'lmjf0226_p3', 'lmjf0226_p4', 'lmjf0226_p5', 'lmjf0226_p6', 'lmjf0226_p7', 'lmjf0226_p8', 'lmjf0226_p9', 'lmjf0226_p10', 'lmjf0226_p11', 'lmjf0226_p12', 'lmjf0226_p13', 'lmjf0226_p14', 'lmjf0226_p15', 'lmjf0226_p16'] | ['October 1 and 2', 'for October 1 and 2.'] | 1 | train |
1,198 | what is the date mentioned in the given information ? | nqjf0226 | ['nqjf0226_p0', 'nqjf0226_p1'] | ['20 April 2006', '20 april 2006'] | 0 | train |
1,199 | What is the meeting time mentioned here? | nqjf0226 | ['nqjf0226_p0', 'nqjf0226_p1'] | ['4:00pm - 5:00pm'] | 0 | train |
1,200 | what is the place mentioned ? | nqjf0226 | ['nqjf0226_p0', 'nqjf0226_p1'] | ['meeting room 403', 'Meeting Room 403'] | 0 | train |
1,201 | Why was it suggested to prepare non-clinical "White paper"? | lmjf0226 | ['lmjf0226_p0', 'lmjf0226_p1', 'lmjf0226_p2', 'lmjf0226_p3', 'lmjf0226_p4', 'lmjf0226_p5', 'lmjf0226_p6', 'lmjf0226_p7', 'lmjf0226_p8', 'lmjf0226_p9', 'lmjf0226_p10', 'lmjf0226_p11', 'lmjf0226_p12', 'lmjf0226_p13', 'lmjf0226_p14', 'lmjf0226_p15', 'lmjf0226_p16'] | ['to address the bladder issue', 'to address the bladder issue.'] | 1 | train |
1,202 | who will forward the article regarding rosiglitazone and non clinical bladder data to andy ? | nqjf0226 | ['nqjf0226_p0', 'nqjf0226_p1'] | ['Mondira'] | 0 | train |
1,204 | Who presented an outline of the Cohen hypothesis? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['Philip Collett'] | 3 | train |
1,205 | What is significant in the development of calculi? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['Raising the pH of male rat urine above 6.5'] | 3 | train |
1,206 | What is the correlation observed in cohen's paper? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['0.61'] | 3 | train |
1,207 | Why didn't rats eliminate calculi as humans do? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['Because rats are quadropeds.', 'Because rats are quadropeds'] | 3 | train |
1,208 | What is the fullform of MAA? | gmjf0226 | ['gmjf0226_p0', 'gmjf0226_p1'] | ['Marketing Authorization Application'] | 0 | train |
1,212 | Who is the Director of Nonclinical Safety and Efficacy? | jsjf0226 | ['jsjf0226_p0', 'jsjf0226_p1'] | ['David Baron', 'David baron'] | 0 | train |
1,213 | Who described tumor promoter-model study? | jsjf0226 | ['jsjf0226_p0', 'jsjf0226_p1'] | ['Dr. El-Hage', 'dr. el-hage'] | 0 | train |
1,214 | What is the duration of daily dosing? | jsjf0226 | ['jsjf0226_p0', 'jsjf0226_p1'] | ['32-weeks', '32-weeks after BBN.'] | 0 | train |
1,215 | Who updated the CEO on August 6? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['Mr. Saito'] | 1 | train |
1,216 | By when should TPNA send outline of response to TCI ? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['by August 19', 'August 19'] | 1 | train |
1,217 | When will Mr. Saito present outline to CEO? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['on August 20', 'August 20'] | 1 | train |
1,219 | When will the FDA Conference Call be held? | fsjf0226 | ['fsjf0226_p0', 'fsjf0226_p1'] | ['July 31, 2002'] | 0 | train |
1,220 | What is the heading of the document? | qtjf0226 | ['qtjf0226_p0'] | ['ACTOS FDA RESPONSE TASK FORCE-TPNA'] | 0 | train |
1,221 | How many key issues does the FDA have with respect to the non-clinical data related to bladder tumors? | qtjf0226 | ['qtjf0226_p0'] | ['The FDA has 3 key issues with respect to the non-clinical data related to bladder tumors.', '3'] | 0 | train |
1,222 | What plan is developed by TPNA? | qtjf0226 | ['qtjf0226_p0'] | ['monitoring plan', 'TPNA will develop monitoring plan.'] | 0 | train |
1,223 | What is TPNA's goal? | qtjf0226 | ['qtjf0226_p0'] | ['is to supply justification to support maintaining current labeling.'] | 0 | train |
1,225 | What is the last point in the table? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['EVALUATE IMPACT ON TAK-559', 'Evaluate Impact on Tak-559'] | 4 | train |
1,227 | What is the Draft's Due Date? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['August 5'] | 4 | train |
1,228 | Which benefit start after 1 year of service? | ttjf0226 | ['ttjf0226_p4'] | ['Extended Disability', 'extended disability'] | 0 | train |
1,229 | What is Ms Wakamatsu's role in Dept. Strategic Development? | lmjf0226 | ['lmjf0226_p0', 'lmjf0226_p1', 'lmjf0226_p2', 'lmjf0226_p3', 'lmjf0226_p4', 'lmjf0226_p5', 'lmjf0226_p6', 'lmjf0226_p7', 'lmjf0226_p8', 'lmjf0226_p9', 'lmjf0226_p10', 'lmjf0226_p11', 'lmjf0226_p12', 'lmjf0226_p13', 'lmjf0226_p14', 'lmjf0226_p15', 'lmjf0226_p16'] | ['Assistant Manager', 'Assistant manager'] | 1 | train |
1,230 | Which drug's toxicity study results will be discussed ? | pljf0226 | ['pljf0226_p0', 'pljf0226_p1', 'pljf0226_p2', 'pljf0226_p3', 'pljf0226_p4', 'pljf0226_p5'] | ['pioglitazone'] | 5 | train |
1,233 | Who challenged authorities regrading implementing monitoring plan? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['Takeda Europe'] | 3 | train |
1,234 | What content is high in male rat urine? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['protein', 'protien content'] | 3 | train |
1,235 | What kind of meeting is mentioned in this letter? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['ACTOS FDA RESPONSE MEETING'] | 0 | train |
1,239 | what kind of drug is used to treat the group of rats? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['pioglitazone', 'Pioglitazone'] | 0 | train |
1,240 | In the rat oncogenicity study, what was observed in male rats? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['thickening of the bladder and hypertrophy of the urothelium'] | 2 | train |
1,241 | What is the due date to conduct review meeting for FDA package? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['August 22'] | 3 | train |
1,242 | What is the time span where no tumors are seen? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['shorter term (12 month)'] | 2 | train |
1,243 | Who is the lead responsible person for the compilation of FDA package? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['Larry Hancock'] | 3 | train |
1,244 | According to mouse oncogenicity study, what was seen male mice only? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['hyperplasia'] | 2 | train |
1,245 | what kind of cell tumours experienced the same frequency when group of rats treated with pioglitazone? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['transitional', 'transitional cell tumors'] | 0 | train |
1,246 | who conducted robust program? | myjf0226 | ['myjf0226_p0', 'myjf0226_p1', 'myjf0226_p2', 'myjf0226_p3'] | ['TCI'] | 2 | train |
1,247 | What is the task assigned to David Baron? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['Send nonclinical rationale/justification section to medical writing for compilation', 'Send nonclinical rationale/justification section to medical writing for compilation.'] | 3 | train |
1,248 | Who is responsible for sending package to TCI/EU for review? | qtjf0226 | ['qtjf0226_p3', 'qtjf0226_p4', 'qtjf0226_p5', 'qtjf0226_p6', 'qtjf0226_p7'] | ['Mary Ramstack'] | 3 | train |
1,253 | Which product's liability claims are described here? | hrjf0226 | ['hrjf0226_p0', 'hrjf0226_p1', 'hrjf0226_p2'] | ['ACTOS PRODUCTS LIABILITY CLAIMS', 'ACTOS PRODUCTS'] | 0 | train |
1,255 | Mention the first name listed in the "apologies"? | ltjf0226 | ['ltjf0226_p0', 'ltjf0226_p1', 'ltjf0226_p2', 'ltjf0226_p3', 'ltjf0226_p4', 'ltjf0226_p5'] | ['Professor Ele Ferrannini'] | 0 | train |
1,256 | What is the exhibit number? | hrjf0226 | ['hrjf0226_p0', 'hrjf0226_p1', 'hrjf0226_p2'] | ['52'] | 0 | train |
1,259 | when was the last meeting/conference call held on ? | ltjf0226 | ['ltjf0226_p0', 'ltjf0226_p1', 'ltjf0226_p2', 'ltjf0226_p3', 'ltjf0226_p4', 'ltjf0226_p5'] | ['15th October 2005', '15 October 2005'] | 0 | train |
1,260 | What is the exhibit number? | jsjf0226 | ['jsjf0226_p0', 'jsjf0226_p1'] | ['107'] | 0 | train |
1,262 | what is the date mentioned under the title - " minutes of conference call"? | ltjf0226 | ['ltjf0226_p0', 'ltjf0226_p1', 'ltjf0226_p2', 'ltjf0226_p3', 'ltjf0226_p4', 'ltjf0226_p5'] | ['28th November 2005', 'Monday 28th November 2005', 'monday 28th november 2005'] | 0 | train |
1,265 | what is the title of chapter 3? | jpjf0226 | ['jpjf0226_p1', 'jpjf0226_p2', 'jpjf0226_p3', 'jpjf0226_p4', 'jpjf0226_p5', 'jpjf0226_p6', 'jpjf0226_p7'] | ['document storage period', 'Document Storage Period'] | 1 | train |
1,266 | What is the graphical representation about? | xqjf0226 | ['xqjf0226_p0', 'xqjf0226_p1', 'xqjf0226_p2', 'xqjf0226_p3'] | ['Summary of Segment Attractiveness'] | 1 | train |
1,267 | On what basis, the Summary of Segment Attractiveness is carried out? | xqjf0226 | ['xqjf0226_p0', 'xqjf0226_p1', 'xqjf0226_p2', 'xqjf0226_p3'] | ['based on current situation & future trends', 'Based on current situation & future trends.', 'current situation & future trends'] | 1 | train |
1,268 | What are the three segments indicated in the graph? | xqjf0226 | ['xqjf0226_p0', 'xqjf0226_p1', 'xqjf0226_p2', 'xqjf0226_p3'] | ['Treatment Machines, Life Negotiators, Struggle for Control'] | 1 | train |
1,270 | What is the conclusion obtained from the graph? | xqjf0226 | ['xqjf0226_p0', 'xqjf0226_p1', 'xqjf0226_p2', 'xqjf0226_p3'] | ['All 3 Segments Have Consistent Needs.', 'All 3 segments have consistent needs'] | 1 | train |
1,272 | what is article 4? | jpjf0226 | ['jpjf0226_p1', 'jpjf0226_p2', 'jpjf0226_p3', 'jpjf0226_p4', 'jpjf0226_p5', 'jpjf0226_p6', 'jpjf0226_p7'] | ['PRINCIPLES OF CREATING DOCUMENTS', 'principles of creating documents', '(PRINCIPLES OF CREATING DOCUMENTS)'] | 0 | train |
1,273 | Semi exclusive rights in how many countries? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['20', '20 countries'] | 1 | train |
1,274 | what is the title of chapter 2? | jpjf0226 | ['jpjf0226_p1', 'jpjf0226_p2', 'jpjf0226_p3', 'jpjf0226_p4', 'jpjf0226_p5', 'jpjf0226_p6', 'jpjf0226_p7'] | ['document storage functions', 'DOCUMENT STORAGE FUNCTIONS'] | 0 | train |
1,276 | What percent is the Supply Price / Royalty Rate? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['30% supply price', '30% SUPPLY PRICE'] | 1 | train |
1,278 | what is article 6? | jpjf0226 | ['jpjf0226_p1', 'jpjf0226_p2', 'jpjf0226_p3', 'jpjf0226_p4', 'jpjf0226_p5', 'jpjf0226_p6', 'jpjf0226_p7'] | ['duties of responsible person in charge of storage and person in charge of storage', 'DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE', '(DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE)'] | 0 | train |
1,279 | In how many countires, license to Exclusive rights are provided? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['60 COUNTRIES', 'in approximately 60 countries', '60'] | 1 | train |
1,280 | what is the name of pediatric program? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['ACTOS', 'ACTOS PEDIATRIC PROGRAM'] | 0 | train |
1,282 | What is the date mentioned in this page? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['5 October 2006'] | 0 | train |
1,294 | What is the title of this page? | ynjf0226 | ['ynjf0226_p15', 'ynjf0226_p16'] | ['Actos plan overview', 'ACTOS PLAN OVERVIEW'] | 1 | train |
1,295 | which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"? | ynjf0226 | ['ynjf0226_p15', 'ynjf0226_p16'] | ["TZD's", "TZD'S"] | 1 | train |
1,301 | What is the Plan TZD Share for the year 2003? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['19.7%'] | 2 | train |
1,303 | Which year has 13.3% Oral share (TZD)? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['2000'] | 2 | train |
1,304 | which has a superior lipid profile(v. avandia and others) under the title of "strength/opportunities? | ynjf0226 | ['ynjf0226_p15', 'ynjf0226_p16'] | ['ACTOS'] | 1 | train |
1,309 | Which study's synopsis is this? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['clinical', 'Clinical Study'] | 3 | train |
1,310 | what is the code mentioned under the title of clinical study synopsis? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['01-06-TL-OPI-527'] | 3 | train |
1,311 | When was expert advisory meeting ? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['4 october 2006', '4 OCTOBER 2006'] | 3 | train |
1,313 | What is the full form of PPSR? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['Proposed Pediatric Study Request', 'PROPOSED PEDIATRIC STUDY REQUEST'] | 2 | train |
1,316 | What study is described in the table given? | hfkf0226 | ['hfkf0226_p0', 'hfkf0226_p1', 'hfkf0226_p2', 'hfkf0226_p3', 'hfkf0226_p4', 'hfkf0226_p5', 'hfkf0226_p6', 'hfkf0226_p7', 'hfkf0226_p8', 'hfkf0226_p9', 'hfkf0226_p10', 'hfkf0226_p11', 'hfkf0226_p12', 'hfkf0226_p13', 'hfkf0226_p14', 'hfkf0226_p15', 'hfkf0226_p16', 'hfkf0226_p17', 'hfkf0226_p18', 'hfkf0226_p19'] | ['PLACEBO- CONTROLLED DOSE RANGING STUDY', 'Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study.'] | 6 | train |
1,317 | Which parameters are considered for the study(see heading of table 2)? | hfkf0226 | ['hfkf0226_p0', 'hfkf0226_p1', 'hfkf0226_p2', 'hfkf0226_p3', 'hfkf0226_p4', 'hfkf0226_p5', 'hfkf0226_p6', 'hfkf0226_p7', 'hfkf0226_p8', 'hfkf0226_p9', 'hfkf0226_p10', 'hfkf0226_p11', 'hfkf0226_p12', 'hfkf0226_p13', 'hfkf0226_p14', 'hfkf0226_p15', 'hfkf0226_p16', 'hfkf0226_p17', 'hfkf0226_p18', 'hfkf0226_p19'] | ['GLYCEMIC', 'Glycemic Parameters'] | 6 | train |
1,318 | Prior to what, the patients entered an 8 week washout/run-in-period? | hfkf0226 | ['hfkf0226_p0', 'hfkf0226_p1', 'hfkf0226_p2', 'hfkf0226_p3', 'hfkf0226_p4', 'hfkf0226_p5', 'hfkf0226_p6', 'hfkf0226_p7', 'hfkf0226_p8', 'hfkf0226_p9', 'hfkf0226_p10', 'hfkf0226_p11', 'hfkf0226_p12', 'hfkf0226_p13', 'hfkf0226_p14', 'hfkf0226_p15', 'hfkf0226_p16', 'hfkf0226_p17', 'hfkf0226_p18', 'hfkf0226_p19'] | ['double-blind treatment'] | 6 | train |
1,320 | What is the floor supply price? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ["$0.17 / 30 mg or Takeda's cost from site of lowest cost"] | 4 | train |
1,321 | What is the royalty adjustment if generic enters the market ? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['50% royalty adjustment', '50%'] | 4 | train |
1,322 | what is the promotional trails data usage for( Lilly in exclusive) ? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['Split of 70/30', 'split of 70/30 (Lilly in exclusive)', 'Split of 70/30 (Lilly in Exclusive)'] | 4 | train |
1,324 | What is the promotional trials data usage for (semi exclusive)? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['50/50 in Semi-exclusive'] | 4 | train |
1,325 | what is the name of the plan review ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['Marketing plan review.', 'MARKETING PLAN REVIEW', 'MARKETING PLAN'] | 0 | train |
1,328 | What is the goal of TPNA? | yljf0226 | ['yljf0226_p0', 'yljf0226_p1'] | ['to supply justification to support maintaining current labeling.'] | 0 | train |
1,329 | what is the first point given in table for bladder cancer alongside of clinical findings ? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['observed during preclinical studies in rats', 'OBSERVED DURING PRECLINICAL STUDIES IN RATS'] | 3 | train |
1,331 | Mention the year given for Actos? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['Actos 2004', '2004'] | 0 | train |
1,333 | what is the percentage of TZD share in the year 2000 ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['40.3%'] | 3 | train |
1,335 | what is Actos TRx (000s) in the year 2003 ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['9,497'] | 3 | train |
1,337 | how much percent of drug quantity present in rezulin under the title of 'clinical findings'? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['1.7%', '1.7'] | 3 | train |
1,339 | what is the percentage of plan TZD share in the year 2004 ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['42.9%'] | 3 | train |
1,340 | how much percent of placebo present in avandia alongside of the clinical findings? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['0.20', '0.20%'] | 3 | train |
1,341 | in which month and the year the launch of Merck's PPAR's took place? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['FEB 2005', 'feb 2005'] | 3 | train |
1,342 | what is the TZD's TRx (000s) in the year 2005 ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['22,902'] | 3 | train |
1,343 | what is the total number of all claims under the title of "summary of litigation risk in the ous territories"? | trjf0226 | ['trjf0226_p0', 'trjf0226_p1', 'trjf0226_p2', 'trjf0226_p3', 'trjf0226_p4', 'trjf0226_p5'] | ['10'] | 3 | train |
1,344 | what is the first TZD used for type 2 patients ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['ACTOS', 'Actos'] | 12 | train |
1,345 | For which type of diabetes the TZD's prescribed earlier in treatment? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['Type 2 diabetes'] | 12 | train |
1,346 | what has to be establish as the the best OAD medication by treating insulin resistance ? | ynjf0226 | ['ynjf0226_p0', 'ynjf0226_p1', 'ynjf0226_p2', 'ynjf0226_p3', 'ynjf0226_p4', 'ynjf0226_p5', 'ynjf0226_p6', 'ynjf0226_p7', 'ynjf0226_p8', 'ynjf0226_p9', 'ynjf0226_p10', 'ynjf0226_p11', 'ynjf0226_p12'] | ['ACTOS', 'Actos'] | 12 | train |
1,347 | What is the Specific example given? | gmjf0226 | ['gmjf0226_p0', 'gmjf0226_p1'] | ['Pioglitazone: Need to commit to studies to investigate certain signals', 'pioglitazone: need to commit to studies to investigate certain signals'] | 1 | train |
1,348 | what is the month and year of overview of submission ? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['NOVEMBER 2006', 'November 2006'] | 1 | train |
1,349 | Which country would have similar interest as in Europe? | gmjf0226 | ['gmjf0226_p0', 'gmjf0226_p1'] | ['USA', 'usa'] | 1 | train |
1,351 | What is the Suggestion from Glyn? | gmjf0226 | ['gmjf0226_p0', 'gmjf0226_p1'] | ["TGRD would formulate direct Risk Management plan and obtain Japan's input", "tgrd would formulate direct risk management plan and obtain japan's input"] | 1 | train |
1,352 | what is the executive summary of bladder cancer cases ? | jfkf0226 | ['jfkf0226_p0', 'jfkf0226_p1', 'jfkf0226_p2', 'jfkf0226_p3'] | ['CONFIRM'] | 1 | train |
1,353 | Full form of PEM? | gmjf0226 | ['gmjf0226_p0', 'gmjf0226_p1'] | ['prescription event monitoring'] | 1 | train |
Subsets and Splits